AI is spitting out more potential drugs than ever. This start-up wants to figure out which ones matter.

AI’s biggest impact in science is Google DeepMind’s use of a deep learning model to predict the complex structures of proteins — the molecules that drive virtually every process in living cells. But as AI models continue to spit out more candidates for potential treatments, there’s an emerging bottleneck: actually characterizing all those candidates in practice, for testing and mass production.